Invex Therapeautics Lands approval for phase three clinical trial in Germany
- Invex Therapeutics (IXC) gains approval to start its IIH EVOLVE phase III clinical trial in Germany to treat patients with idiopathic intracranial hypertension (IIH) using Presendin
- The approval was received from Germany’s Federal Institute for Drugs and Medical Devices and marks another step towards the commercialisation of Presendin
- The trial will test 240 patients with newly-diagnosed IIH to assess the efficacy and safety of Presending versus a placebo
- Invex entered an exclusive collaboration, manufacturing and supply agreement back in September 2021 with Peptron for Presendin in IIH for all major markets except for South Korea
- IXC shares are up 2.22 per cent to 46 cents at 10:46 am AEDT
